These GU diagnoses are courtesy of my colleague Kenneth Iczkowski, M.D. who specializes in GU pathology:
PROSTATE
BIOPSIES
Benign
– Benign prostatic tissue
(if applicable) with: Chronic inflammation. Acute inflammation. Atrophy (degree).
– Benign fibromuscular stroma
Cancer, Grade group 1
– Prostatic adenocarcinoma, Gleason 3+3 (score = 6, Grade group 1) within ***% of *** out of *** cores, tumor length *** mm
Cancer, Grade group 2
– Prostatic adenocarcinoma, Gleason 3+4 (score = 7, Grade group 2) within ***% of *** out of *** cores, tumor length *** mm
– ***% of tumor is Gleason 4 and *** cribriform
Cancer, Grade group 3
– Prostatic adenocarcinoma, Gleason 4+3 (score = 7, Grade group 3) within ***% of *** out of *** cores, tumor length *** mm
– ***% of tumor is Gleason 4 and *** cribriform
Cancer, Grade group 4
– Prostatic adenocarcinoma, Gleason 4+4 (score = 8, Grade group 4) within ***% of *** out of *** cores, tumor length *** mm
– Tumor *** cribriform
Cancer, Grade group 5
– Prostatic adenocarcinoma, Gleason 4+5 (score = 9, Grade group 5) within ***% of *** out of *** cores, tumor length *** mm
Comment at end of most diagnoses whenever there is cancer (if applicable):
Comment: Tumor shows no perieneural invasion or extraprostatic extension. OR
Comment: Tumor shows no extraprostatic extension.
PROSTATECTOMY
LYMPH NODES, LEFT ILIAC (LYMPHADENECTOMY)
– Five lymph nodes negative for tumor (0/5)
PROSTATE AND SEMINAL VESICLES (PROSTATECTOMY)
– Prostatic adenocarcinoma, Gleason ***+*** (score =***, Grade group ***), see template
– ***% of tumor is Gleason 4 pattern
– Large cribriform pattern ***
– Extraprostatic extension ***
– Margin ***
TRANSURETHRAL RESECTION
PROSTATE (TRANSURETHRAL RESECTION)
– Glandular and stromal hyperplasia, benign
– Focal chronic inflammation
OR
– Prostatic adenocarcinoma, Gleason 3+3 (score = 6, Grade group 1) within ***% of chips (*** out of *** chips)
KIDNEY
KIDNEY, RIGHT, (NEPHRECTOMY)
– Clear cell renal cell carcinoma, 8.0 cm, within upper pole
– ISUP nucleolar grade 3 (of 4)
– Tumor shows no necrosis, lymphovascular invasion, or sarcomatoid component
OR
– 10% of tumor demonstrates a sarcomatoid component (slide C5)
– Tumor invades into perirenal fat (slide C8) (AJCC Stage pT3a)
RADICAL:
– Vascular and ureteral margins negative for tumor; parenchymal resection margins negative for tumor (closest approach 1 mm, slide C8)
PARTIAL:
– Parenchymal margin negative for tumor (closest approach 2 mm)
– Non-neoplastic kidney with: 20% glomerulosclerosis, vessels with moderate arteriolosclerosis, interstitium with focal chronic inflammation; tubules without abnormality
For chromophobe:
Comment: It is the current recommendation that chromophobe renal cell carcinoma should not be graded using the ISUP nucleolar or Fuhrman grading schemes (Am J Surg Pathol 2013;37:311-322.)
Link to this article on PubMed
BLADDER
URINARY BLADDER, LEFT WALL (BIOPSY)
– Urothelium, negative for tumor or dysplasia
– Muscularis propria *** present
OR
– Urothelial carcinoma, *** grade (ISUP)
– Tumor invades lamina propria (Stage pT1)
– *** for lymphovascular invasion
– Muscularis propria *** present and is ***
URINARY BLADDER AND PROSTATE (CYSTOPROSTATECTOMY)
Urinary bladder:
– Single microscopic focus (2 mm) of residual, high-grade urothelial carcinoma is noted within muscularis propria (Stage pT2 N2) at the posterior dome
– Posterior dome has ulcer bed with foreign body giant cell reaction, calcium, and necroinflammatory debris
– Remainder of bladder with reactive urothelium and edema; fat necrosis noted in adipose tissue (Slide L11)
Prostate and seminal vesicles:
– Prostatic adenocarcinoma, Gleason 3+4 (score =7; 5% is pattern 4), bilateral and multifocal, within 25% of gland
– Tumor forms dominant nodules in the right anterior peripheral zone (levels 1–6) measuring up to 14 mm and the left anterior peripheral zone (levels 1–6) measuring up to 14 mm
– Negative for extraprostatic extension (Stage pT2)
– Resection margins negative for tumor
– Seminal vesicles and vasa deferentia negative for tumor
– Non-neoplastic prostate with nodular glandular and stromal hyperplasia
Last updated: 11/18/23